nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PTGS2—muscle cancer	0.573	1	CbGaD
Mesalazine—PTGS2—Etoposide—muscle cancer	0.0417	0.542	CbGbCtD
Mesalazine—PTGS1—Etoposide—muscle cancer	0.0352	0.458	CbGbCtD
Mesalazine—PPARG—hindlimb—muscle cancer	0.00638	0.0973	CbGeAlD
Mesalazine—PPARG—appendage—muscle cancer	0.00548	0.0835	CbGeAlD
Mesalazine—PPARG—Teniposide—Etoposide—muscle cancer	0.00373	1	CbGdCrCtD
Mesalazine—PTGS2—hindlimb—muscle cancer	0.00326	0.0497	CbGeAlD
Mesalazine—CHUK—renal system—muscle cancer	0.00325	0.0496	CbGeAlD
Mesalazine—IKBKB—embryo—muscle cancer	0.00292	0.0446	CbGeAlD
Mesalazine—PTGS2—appendage—muscle cancer	0.0028	0.0427	CbGeAlD
Mesalazine—IKBKB—smooth muscle tissue—muscle cancer	0.0023	0.035	CbGeAlD
Mesalazine—CHUK—head—muscle cancer	0.00218	0.0332	CbGeAlD
Mesalazine—CHUK—testis—muscle cancer	0.0021	0.0321	CbGeAlD
Mesalazine—ALOX5—smooth muscle tissue—muscle cancer	0.0019	0.029	CbGeAlD
Mesalazine—PPARG—embryo—muscle cancer	0.00182	0.0277	CbGeAlD
Mesalazine—IKBKB—tendon—muscle cancer	0.00173	0.0263	CbGeAlD
Mesalazine—IKBKB—vagina—muscle cancer	0.0016	0.0244	CbGeAlD
Mesalazine—MPO—renal system—muscle cancer	0.00155	0.0237	CbGeAlD
Mesalazine—IKBKB—head—muscle cancer	0.00148	0.0226	CbGeAlD
Mesalazine—PPARG—smooth muscle tissue—muscle cancer	0.00143	0.0218	CbGeAlD
Mesalazine—IKBKB—testis—muscle cancer	0.00143	0.0218	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—muscle cancer	0.00139	0.3	CrCbGaD
Mesalazine—ALOX5—bone marrow—muscle cancer	0.00139	0.0211	CbGeAlD
Mesalazine—PPARG—renal system—muscle cancer	0.00138	0.021	CbGeAlD
Mesalazine—ALOX5—head—muscle cancer	0.00123	0.0187	CbGeAlD
Mesalazine—ALOX5—testis—muscle cancer	0.00118	0.0181	CbGeAlD
Mesalazine—MPO—bone marrow—muscle cancer	0.00117	0.0179	CbGeAlD
Mesalazine—PPARG—tendon—muscle cancer	0.00107	0.0164	CbGeAlD
Mesalazine—PPARG—bone marrow—muscle cancer	0.00104	0.0159	CbGeAlD
Mesalazine—MPO—head—muscle cancer	0.00104	0.0158	CbGeAlD
Mesalazine—MPO—testis—muscle cancer	0.001	0.0153	CbGeAlD
Mesalazine—PPARG—vagina—muscle cancer	0.000997	0.0152	CbGeAlD
Mesalazine—Olsalazine—PTGS2—muscle cancer	0.000951	0.206	CrCbGaD
Mesalazine—PTGS2—embryo—muscle cancer	0.000929	0.0142	CbGeAlD
Mesalazine—PPARG—head—muscle cancer	0.000921	0.014	CbGeAlD
Mesalazine—Diflunisal—PTGS2—muscle cancer	0.000894	0.193	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—muscle cancer	0.000894	0.193	CrCbGaD
Mesalazine—PPARG—testis—muscle cancer	0.00089	0.0136	CbGeAlD
Mesalazine—PTGS1—smooth muscle tissue—muscle cancer	0.000764	0.0117	CbGeAlD
Mesalazine—PTGS1—renal system—muscle cancer	0.000736	0.0112	CbGeAlD
Mesalazine—PTGS2—smooth muscle tissue—muscle cancer	0.000731	0.0111	CbGeAlD
Mesalazine—PTGS2—renal system—muscle cancer	0.000703	0.0107	CbGeAlD
Mesalazine—PTGS1—cardiac atrium—muscle cancer	0.000659	0.01	CbGeAlD
Mesalazine—PTGS1—tendon—muscle cancer	0.000574	0.00876	CbGeAlD
Mesalazine—PTGS2—tendon—muscle cancer	0.000549	0.00837	CbGeAlD
Mesalazine—PTGS1—vagina—muscle cancer	0.000533	0.00813	CbGeAlD
Mesalazine—PTGS2—bone marrow—muscle cancer	0.000532	0.00811	CbGeAlD
Mesalazine—PTGS2—vagina—muscle cancer	0.000509	0.00777	CbGeAlD
Mesalazine—Salicylic acid—PTGS2—muscle cancer	0.000497	0.108	CrCbGaD
Mesalazine—PTGS1—head—muscle cancer	0.000492	0.00751	CbGeAlD
Mesalazine—CHUK—Apoptosis—IGF2—muscle cancer	0.000492	0.00472	CbGpPWpGaD
Mesalazine—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—FOXO1—muscle cancer	0.000492	0.00472	CbGpPWpGaD
Mesalazine—MPO—C-MYB transcription factor network—PTGS2—muscle cancer	0.000477	0.00458	CbGpPWpGaD
Mesalazine—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000477	0.00458	CbGpPWpGaD
Mesalazine—PTGS1—testis—muscle cancer	0.000476	0.00725	CbGeAlD
Mesalazine—PTGS2—head—muscle cancer	0.000471	0.00718	CbGeAlD
Mesalazine—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—muscle cancer	0.00046	0.00441	CbGpPWpGaD
Mesalazine—MPO—Selenium Micronutrient Network—PTGS2—muscle cancer	0.00046	0.00441	CbGpPWpGaD
Mesalazine—IKBKB—Leptin signaling pathway—FOXO1—muscle cancer	0.000449	0.00431	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—IGF2—muscle cancer	0.000446	0.00428	CbGpPWpGaD
Mesalazine—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.000445	0.00427	CbGpPWpGaD
Mesalazine—CHUK—Constitutive PI3K/AKT Signaling in Cancer—FOXO1—muscle cancer	0.000444	0.00426	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000434	0.00417	CbGpPWpGaD
Mesalazine—ALOX5—Selenium Micronutrient Network—PTGS2—muscle cancer	0.000434	0.00416	CbGpPWpGaD
Mesalazine—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—muscle cancer	0.000422	0.00405	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—FOXO4—muscle cancer	0.000405	0.00388	CbGpPWpGaD
Mesalazine—CHUK—B Cell Receptor Signaling Pathway—FOXO1—muscle cancer	0.000403	0.00387	CbGpPWpGaD
Mesalazine—PTGS2—S1P1 pathway—VEGFA—muscle cancer	0.000401	0.00385	CbGpPWpGaD
Mesalazine—CHUK—PI-3K cascade—FOXO1—muscle cancer	0.0004	0.00384	CbGpPWpGaD
Mesalazine—CHUK—Validated transcriptional targets of TAp63 isoforms—CDKN2A—muscle cancer	0.000399	0.00382	CbGpPWpGaD
Mesalazine—CHUK—BDNF signaling pathway—CNR1—muscle cancer	0.000391	0.00375	CbGpPWpGaD
Mesalazine—CHUK—PI3K/AKT activation—FOXO1—muscle cancer	0.000391	0.00374	CbGpPWpGaD
Mesalazine—CHUK—GAB1 signalosome—FOXO1—muscle cancer	0.000387	0.00372	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling of activated FGFR—FOXO4—muscle cancer	0.000387	0.00371	CbGpPWpGaD
Mesalazine—CHUK—Validated transcriptional targets of TAp63 isoforms—MDM2—muscle cancer	0.000387	0.00371	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—FOXO4—muscle cancer	0.000381	0.00366	CbGpPWpGaD
Mesalazine—CHUK—Role of LAT2/NTAL/LAB on calcium mobilization—FOXO1—muscle cancer	0.000379	0.00363	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MYOG—muscle cancer	0.000377	0.00361	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Receptor Signaling Pathway—FOXO1—muscle cancer	0.000366	0.00351	CbGpPWpGaD
Mesalazine—CHUK—Downstream signal transduction—FOXO4—muscle cancer	0.000364	0.00349	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—FOXO4—muscle cancer	0.000362	0.00347	CbGpPWpGaD
Mesalazine—PPARG—Regulation of retinoblastoma protein—CDKN2A—muscle cancer	0.000362	0.00347	CbGpPWpGaD
Mesalazine—IKBKB—Validated transcriptional targets of TAp63 isoforms—CDKN2A—muscle cancer	0.000362	0.00347	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—FOXO4—muscle cancer	0.000361	0.00346	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—FOXO4—muscle cancer	0.000359	0.00344	CbGpPWpGaD
Mesalazine—IKBKB—BDNF signaling pathway—CNR1—muscle cancer	0.000354	0.0034	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—FOXO4—muscle cancer	0.000354	0.00339	CbGpPWpGaD
Mesalazine—PPARG—Regulation of retinoblastoma protein—MDM2—muscle cancer	0.000351	0.00336	CbGpPWpGaD
Mesalazine—IKBKB—Validated transcriptional targets of TAp63 isoforms—MDM2—muscle cancer	0.000351	0.00336	CbGpPWpGaD
Mesalazine—MPO—Folate Metabolism—TP53—muscle cancer	0.000345	0.0033	CbGpPWpGaD
Mesalazine—PPARG—Adipogenesis—FOXO1—muscle cancer	0.00034	0.00326	CbGpPWpGaD
Mesalazine—CHUK—Constitutive PI3K/AKT Signaling in Cancer—KIT—muscle cancer	0.000338	0.00324	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—FOXO4—muscle cancer	0.000338	0.00324	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—FOXO4—muscle cancer	0.000338	0.00324	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	0.000338	0.00324	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—FOXO4—muscle cancer	0.000335	0.00321	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—FOXO4—muscle cancer	0.000332	0.00318	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—FOXO4—muscle cancer	0.00033	0.00317	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—FOXO4—muscle cancer	0.000321	0.00307	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000318	0.00305	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—FOXO4—muscle cancer	0.000312	0.003	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000307	0.00294	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	0.000306	0.00293	CbGpPWpGaD
Mesalazine—CHUK—PI-3K cascade—KIT—muscle cancer	0.000305	0.00292	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—FOXO1—muscle cancer	0.000299	0.00287	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.000299	0.00287	CbGpPWpGaD
Mesalazine—CHUK—PI3K/AKT activation—KIT—muscle cancer	0.000298	0.00285	CbGpPWpGaD
Mesalazine—PTGS1—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000296	0.00284	CbGpPWpGaD
Mesalazine—CHUK—GAB1 signalosome—KIT—muscle cancer	0.000295	0.00283	CbGpPWpGaD
Mesalazine—CHUK—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—muscle cancer	0.000288	0.00277	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling of activated FGFR—FOXO1—muscle cancer	0.000286	0.00274	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—FOXO4—muscle cancer	0.000283	0.00272	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000283	0.00271	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—FOXO1—muscle cancer	0.000282	0.0027	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—CDKN2A—muscle cancer	0.00028	0.00268	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—MDM2—muscle cancer	0.000272	0.0026	CbGpPWpGaD
Mesalazine—CHUK—Downstream signal transduction—FOXO1—muscle cancer	0.000269	0.00258	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—FOXO1—muscle cancer	0.000268	0.00257	CbGpPWpGaD
Mesalazine—CHUK—Constitutive PI3K/AKT Signaling in Cancer—MDM2—muscle cancer	0.000267	0.00256	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—FOXO1—muscle cancer	0.000266	0.00255	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—FOXO1—muscle cancer	0.000265	0.00254	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	0.000261	0.0025	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000257	0.00247	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—CDKN2A—muscle cancer	0.000254	0.00243	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—FOXO1—muscle cancer	0.000249	0.00239	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.000249	0.00239	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—FOXO1—muscle cancer	0.000249	0.00239	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—FOXO1—muscle cancer	0.000247	0.00237	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—MDM2—muscle cancer	0.000246	0.00236	CbGpPWpGaD
Mesalazine—IKBKB—Insulin Signaling—FOXO1—muscle cancer	0.000245	0.00235	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—FOXO1—muscle cancer	0.000245	0.00235	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—FOXO1—muscle cancer	0.000244	0.00234	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—FH—muscle cancer	0.000242	0.00232	CbGpPWpGaD
Mesalazine—CHUK—PI-3K cascade—MDM2—muscle cancer	0.00024	0.0023	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis Modulation and Signaling—CDKN2A—muscle cancer	0.000238	0.00228	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	0.000237	0.00227	CbGpPWpGaD
Mesalazine—CHUK—PI3K/AKT activation—MDM2—muscle cancer	0.000234	0.00225	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MYOD1—muscle cancer	0.000233	0.00223	CbGpPWpGaD
Mesalazine—CHUK—GAB1 signalosome—MDM2—muscle cancer	0.000233	0.00223	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—FOXO1—muscle cancer	0.000231	0.00221	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—FOXO4—muscle cancer	0.00023	0.0022	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—KIT—muscle cancer	0.000228	0.00218	CbGpPWpGaD
Mesalazine—CHUK—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—muscle cancer	0.000227	0.00218	CbGpPWpGaD
Mesalazine—PPARG—Generic Transcription Pathway—MED12—muscle cancer	0.000226	0.00217	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.000226	0.00217	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.000221	0.00212	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling of activated FGFR—KIT—muscle cancer	0.000218	0.00209	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—KIT—muscle cancer	0.000215	0.00206	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MED12—muscle cancer	0.000213	0.00204	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—FOXO1—muscle cancer	0.000209	0.00201	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—FOXO4—muscle cancer	0.000209	0.002	CbGpPWpGaD
Mesalazine—CHUK—Downstream signal transduction—KIT—muscle cancer	0.000205	0.00196	CbGpPWpGaD
Mesalazine—PTGS2—C-MYB transcription factor network—KIT—muscle cancer	0.000204	0.00196	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—KIT—muscle cancer	0.000204	0.00196	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—KIT—muscle cancer	0.000203	0.00195	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—KIT—muscle cancer	0.000202	0.00194	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	0.000199	0.00191	CbGpPWpGaD
Mesalazine—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.000198	0.0019	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.00019	0.00182	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.00019	0.00182	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—KIT—muscle cancer	0.00019	0.00182	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—KIT—muscle cancer	0.00019	0.00182	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—KIT—muscle cancer	0.000188	0.00181	CbGpPWpGaD
Mesalazine—PTGS1—Selenium Micronutrient Network—PTGS2—muscle cancer	0.000188	0.0018	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000188	0.0018	CbGpPWpGaD
Mesalazine—CHUK—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	0.000187	0.00179	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000187	0.00179	CbGpPWpGaD
Mesalazine—Blood creatinine increased—Doxorubicin—muscle cancer	0.000186	0.00108	CcSEcCtD
Mesalazine—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	0.000186	0.00178	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—KIT—muscle cancer	0.000186	0.00178	CbGpPWpGaD
Mesalazine—Neutropenia—Methotrexate—muscle cancer	0.000185	0.00108	CcSEcCtD
Mesalazine—Dysuria—Methotrexate—muscle cancer	0.000185	0.00108	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—CD34—muscle cancer	0.000185	0.00178	CbGpPWpGaD
Mesalazine—Thrombocytopenia—Etoposide—muscle cancer	0.000184	0.00107	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000184	0.00107	CcSEcCtD
Mesalazine—Tachycardia—Etoposide—muscle cancer	0.000184	0.00107	CcSEcCtD
Mesalazine—Body temperature increased—Vincristine—muscle cancer	0.000184	0.00107	CcSEcCtD
Mesalazine—Abdominal pain—Vincristine—muscle cancer	0.000184	0.00107	CcSEcCtD
Mesalazine—Liver function test abnormal—Doxorubicin—muscle cancer	0.000183	0.00107	CcSEcCtD
Mesalazine—Skin disorder—Etoposide—muscle cancer	0.000183	0.00106	CcSEcCtD
Mesalazine—CHUK—p75(NTR)-mediated signaling—TP53—muscle cancer	0.000182	0.00175	CbGpPWpGaD
Mesalazine—Dry skin—Doxorubicin—muscle cancer	0.000182	0.00106	CcSEcCtD
Mesalazine—Hyperhidrosis—Etoposide—muscle cancer	0.000182	0.00106	CcSEcCtD
Mesalazine—Abdominal pain upper—Doxorubicin—muscle cancer	0.000181	0.00105	CcSEcCtD
Mesalazine—Orthostatic hypotension—Doxorubicin—muscle cancer	0.000181	0.00105	CcSEcCtD
Mesalazine—Photosensitivity reaction—Methotrexate—muscle cancer	0.000181	0.00105	CcSEcCtD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	0.00018	0.00173	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—MDM2—muscle cancer	0.000179	0.00172	CbGpPWpGaD
Mesalazine—Breast disorder—Doxorubicin—muscle cancer	0.000179	0.00104	CcSEcCtD
Mesalazine—Anorexia—Etoposide—muscle cancer	0.000179	0.00104	CcSEcCtD
Mesalazine—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000179	0.00104	CcSEcCtD
Mesalazine—Diarrhoea—Dactinomycin—muscle cancer	0.000178	0.00103	CcSEcCtD
Mesalazine—Pneumonia—Methotrexate—muscle cancer	0.000178	0.00103	CcSEcCtD
Mesalazine—Nasopharyngitis—Doxorubicin—muscle cancer	0.000178	0.00103	CcSEcCtD
Mesalazine—Infestation NOS—Methotrexate—muscle cancer	0.000177	0.00103	CcSEcCtD
Mesalazine—Infestation—Methotrexate—muscle cancer	0.000177	0.00103	CcSEcCtD
Mesalazine—Depression—Methotrexate—muscle cancer	0.000176	0.00102	CcSEcCtD
Mesalazine—CHUK—B Cell Activation—KIT—muscle cancer	0.000176	0.00169	CbGpPWpGaD
Mesalazine—Hypotension—Etoposide—muscle cancer	0.000176	0.00102	CcSEcCtD
Mesalazine—Gastritis—Doxorubicin—muscle cancer	0.000176	0.00102	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000175	0.00102	CcSEcCtD
Mesalazine—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000175	0.00102	CcSEcCtD
Mesalazine—Renal failure—Methotrexate—muscle cancer	0.000174	0.00101	CcSEcCtD
Mesalazine—Abdominal distension—Doxorubicin—muscle cancer	0.000173	0.001	CcSEcCtD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000172	0.00165	CbGpPWpGaD
Mesalazine—Stomatitis—Methotrexate—muscle cancer	0.000172	0.001	CcSEcCtD
Mesalazine—Conjunctivitis—Methotrexate—muscle cancer	0.000172	0.000999	CcSEcCtD
Mesalazine—CHUK—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000172	0.00165	CbGpPWpGaD
Mesalazine—Asthma—Doxorubicin—muscle cancer	0.000172	0.000998	CcSEcCtD
Mesalazine—Influenza—Doxorubicin—muscle cancer	0.000172	0.000998	CcSEcCtD
Mesalazine—Dysphagia—Doxorubicin—muscle cancer	0.000172	0.000998	CcSEcCtD
Mesalazine—Hypersensitivity—Vincristine—muscle cancer	0.000171	0.000995	CcSEcCtD
Mesalazine—Eosinophilia—Doxorubicin—muscle cancer	0.00017	0.000988	CcSEcCtD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.00017	0.00163	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—FOXO1—muscle cancer	0.00017	0.00163	CbGpPWpGaD
Mesalazine—Sweating—Methotrexate—muscle cancer	0.000169	0.000985	CcSEcCtD
Mesalazine—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	0.000169	0.00162	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—MDM2—muscle cancer	0.000169	0.00162	CbGpPWpGaD
Mesalazine—Paraesthesia—Etoposide—muscle cancer	0.000169	0.000982	CcSEcCtD
Mesalazine—Haematuria—Methotrexate—muscle cancer	0.000168	0.00098	CcSEcCtD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000168	0.00161	CbGpPWpGaD
Mesalazine—Pancreatitis—Doxorubicin—muscle cancer	0.000168	0.000978	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—CD34—muscle cancer	0.000168	0.00161	CbGpPWpGaD
Mesalazine—Dyspnoea—Etoposide—muscle cancer	0.000168	0.000975	CcSEcCtD
Mesalazine—Somnolence—Etoposide—muscle cancer	0.000167	0.000973	CcSEcCtD
Mesalazine—Angina pectoris—Doxorubicin—muscle cancer	0.000167	0.000972	CcSEcCtD
Mesalazine—Hepatobiliary disease—Methotrexate—muscle cancer	0.000167	0.000972	CcSEcCtD
Mesalazine—Epistaxis—Methotrexate—muscle cancer	0.000167	0.000969	CcSEcCtD
Mesalazine—Asthenia—Vincristine—muscle cancer	0.000167	0.000969	CcSEcCtD
Mesalazine—PTGS2—C-MYB transcription factor network—CDKN2A—muscle cancer	0.000166	0.00159	CbGpPWpGaD
Mesalazine—IKBKB—p75(NTR)-mediated signaling—TP53—muscle cancer	0.000165	0.00159	CbGpPWpGaD
Mesalazine—Vomiting—Dactinomycin—muscle cancer	0.000165	0.000961	CcSEcCtD
Mesalazine—Bronchitis—Doxorubicin—muscle cancer	0.000165	0.00096	CcSEcCtD
Mesalazine—Agranulocytosis—Methotrexate—muscle cancer	0.000165	0.000959	CcSEcCtD
Mesalazine—Rash—Dactinomycin—muscle cancer	0.000164	0.000953	CcSEcCtD
Mesalazine—Decreased appetite—Etoposide—muscle cancer	0.000164	0.000951	CcSEcCtD
Mesalazine—Pancytopenia—Doxorubicin—muscle cancer	0.000163	0.000948	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Etoposide—muscle cancer	0.000162	0.000945	CcSEcCtD
Mesalazine—Fatigue—Etoposide—muscle cancer	0.000162	0.000943	CcSEcCtD
Mesalazine—CHUK—Downstream signal transduction—MDM2—muscle cancer	0.000161	0.00155	CbGpPWpGaD
Mesalazine—Pain—Etoposide—muscle cancer	0.000161	0.000936	CcSEcCtD
Mesalazine—Constipation—Etoposide—muscle cancer	0.000161	0.000936	CcSEcCtD
Mesalazine—CHUK—Signaling by FGFR—MDM2—muscle cancer	0.000161	0.00154	CbGpPWpGaD
Mesalazine—Neutropenia—Doxorubicin—muscle cancer	0.00016	0.000933	CcSEcCtD
Mesalazine—Dysuria—Doxorubicin—muscle cancer	0.00016	0.000933	CcSEcCtD
Mesalazine—CHUK—Signaling by ERBB2—MDM2—muscle cancer	0.00016	0.00153	CbGpPWpGaD
Mesalazine—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000159	0.000927	CcSEcCtD
Mesalazine—Haemoglobin—Methotrexate—muscle cancer	0.000159	0.000927	CcSEcCtD
Mesalazine—IKBKB—B Cell Activation—KIT—muscle cancer	0.000159	0.00153	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—MDM2—muscle cancer	0.000159	0.00152	CbGpPWpGaD
Mesalazine—Diarrhoea—Vincristine—muscle cancer	0.000159	0.000924	CcSEcCtD
Mesalazine—Haemorrhage—Methotrexate—muscle cancer	0.000159	0.000922	CcSEcCtD
Mesalazine—Hepatitis—Methotrexate—muscle cancer	0.000159	0.000922	CcSEcCtD
Mesalazine—Pollakiuria—Doxorubicin—muscle cancer	0.000159	0.000922	CcSEcCtD
Mesalazine—Pharyngitis—Methotrexate—muscle cancer	0.000157	0.000916	CcSEcCtD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000157	0.0015	CbGpPWpGaD
Mesalazine—Urinary tract disorder—Methotrexate—muscle cancer	0.000157	0.000911	CcSEcCtD
Mesalazine—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000157	0.000911	CcSEcCtD
Mesalazine—Weight increased—Doxorubicin—muscle cancer	0.000156	0.000908	CcSEcCtD
Mesalazine—CHUK—Apoptosis—TP53—muscle cancer	0.000156	0.00149	CbGpPWpGaD
Mesalazine—Urethral disorder—Methotrexate—muscle cancer	0.000155	0.000904	CcSEcCtD
Mesalazine—Weight decreased—Doxorubicin—muscle cancer	0.000155	0.000903	CcSEcCtD
Mesalazine—Feeling abnormal—Etoposide—muscle cancer	0.000155	0.000902	CcSEcCtD
Mesalazine—Nausea—Dactinomycin—muscle cancer	0.000154	0.000898	CcSEcCtD
Mesalazine—IKBKB—Signaling by NGF—FOXO1—muscle cancer	0.000154	0.00148	CbGpPWpGaD
Mesalazine—Pneumonia—Doxorubicin—muscle cancer	0.000154	0.000895	CcSEcCtD
Mesalazine—Gastrointestinal pain—Etoposide—muscle cancer	0.000154	0.000895	CcSEcCtD
Mesalazine—Dizziness—Vincristine—muscle cancer	0.000154	0.000893	CcSEcCtD
Mesalazine—Infestation NOS—Doxorubicin—muscle cancer	0.000153	0.00089	CcSEcCtD
Mesalazine—Infestation—Doxorubicin—muscle cancer	0.000153	0.00089	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000152	0.000882	CcSEcCtD
Mesalazine—Renal failure—Doxorubicin—muscle cancer	0.00015	0.000875	CcSEcCtD
Mesalazine—Erythema multiforme—Methotrexate—muscle cancer	0.00015	0.000872	CcSEcCtD
Mesalazine—Neuropathy peripheral—Doxorubicin—muscle cancer	0.00015	0.000872	CcSEcCtD
Mesalazine—PPARG—Metabolism—FH—muscle cancer	0.00015	0.00144	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.00015	0.00143	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—MDM2—muscle cancer	0.00015	0.00143	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—MDM2—muscle cancer	0.00015	0.00143	CbGpPWpGaD
Mesalazine—Urticaria—Etoposide—muscle cancer	0.000149	0.000869	CcSEcCtD
Mesalazine—Jaundice—Doxorubicin—muscle cancer	0.000149	0.000867	CcSEcCtD
Mesalazine—Stomatitis—Doxorubicin—muscle cancer	0.000149	0.000867	CcSEcCtD
Mesalazine—Body temperature increased—Etoposide—muscle cancer	0.000149	0.000865	CcSEcCtD
Mesalazine—Abdominal pain—Etoposide—muscle cancer	0.000149	0.000865	CcSEcCtD
Mesalazine—Urinary tract infection—Doxorubicin—muscle cancer	0.000149	0.000865	CcSEcCtD
Mesalazine—Conjunctivitis—Doxorubicin—muscle cancer	0.000149	0.000865	CcSEcCtD
Mesalazine—CHUK—Signaling by EGFR—MDM2—muscle cancer	0.000148	0.00142	CbGpPWpGaD
Mesalazine—Eye disorder—Methotrexate—muscle cancer	0.000148	0.000862	CcSEcCtD
Mesalazine—Tinnitus—Methotrexate—muscle cancer	0.000148	0.00086	CcSEcCtD
Mesalazine—Vomiting—Vincristine—muscle cancer	0.000148	0.000859	CcSEcCtD
Mesalazine—Cardiac disorder—Methotrexate—muscle cancer	0.000147	0.000856	CcSEcCtD
Mesalazine—CHUK—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000147	0.00141	CbGpPWpGaD
Mesalazine—Sweating—Doxorubicin—muscle cancer	0.000147	0.000853	CcSEcCtD
Mesalazine—Rash—Vincristine—muscle cancer	0.000146	0.000852	CcSEcCtD
Mesalazine—CHUK—Signaling by PDGF—MDM2—muscle cancer	0.000146	0.0014	CbGpPWpGaD
Mesalazine—Dermatitis—Vincristine—muscle cancer	0.000146	0.000851	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—KIDINS220—muscle cancer	0.000146	0.0014	CbGpPWpGaD
Mesalazine—Haematuria—Doxorubicin—muscle cancer	0.000146	0.000848	CcSEcCtD
Mesalazine—Headache—Vincristine—muscle cancer	0.000145	0.000846	CcSEcCtD
Mesalazine—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000145	0.000842	CcSEcCtD
Mesalazine—Epistaxis—Doxorubicin—muscle cancer	0.000144	0.000839	CcSEcCtD
Mesalazine—Angiopathy—Methotrexate—muscle cancer	0.000144	0.000837	CcSEcCtD
Mesalazine—Sinusitis—Doxorubicin—muscle cancer	0.000144	0.000835	CcSEcCtD
Mesalazine—Immune system disorder—Methotrexate—muscle cancer	0.000143	0.000833	CcSEcCtD
Mesalazine—Mediastinal disorder—Methotrexate—muscle cancer	0.000143	0.000831	CcSEcCtD
Mesalazine—Agranulocytosis—Doxorubicin—muscle cancer	0.000143	0.00083	CcSEcCtD
Mesalazine—Chills—Methotrexate—muscle cancer	0.000142	0.000828	CcSEcCtD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000142	0.00136	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—TP53—muscle cancer	0.000141	0.00135	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000141	0.00135	CbGpPWpGaD
Mesalazine—Alopecia—Methotrexate—muscle cancer	0.00014	0.000815	CcSEcCtD
Mesalazine—Mental disorder—Methotrexate—muscle cancer	0.000139	0.000808	CcSEcCtD
Mesalazine—Hypersensitivity—Etoposide—muscle cancer	0.000139	0.000806	CcSEcCtD
Mesalazine—CHUK—B Cell Activation—MDM2—muscle cancer	0.000138	0.00133	CbGpPWpGaD
Mesalazine—Erythema—Methotrexate—muscle cancer	0.000138	0.000803	CcSEcCtD
Mesalazine—Haemoglobin—Doxorubicin—muscle cancer	0.000138	0.000803	CcSEcCtD
Mesalazine—Nausea—Vincristine—muscle cancer	0.000138	0.000802	CcSEcCtD
Mesalazine—Rhinitis—Doxorubicin—muscle cancer	0.000138	0.000801	CcSEcCtD
Mesalazine—Hepatitis—Doxorubicin—muscle cancer	0.000137	0.000799	CcSEcCtD
Mesalazine—Haemorrhage—Doxorubicin—muscle cancer	0.000137	0.000799	CcSEcCtD
Mesalazine—ALOX5—Metabolism—MED12—muscle cancer	0.000137	0.00131	CbGpPWpGaD
Mesalazine—Pharyngitis—Doxorubicin—muscle cancer	0.000136	0.000793	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000136	0.0013	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000136	0.0013	CbGpPWpGaD
Mesalazine—Urinary tract disorder—Doxorubicin—muscle cancer	0.000136	0.000789	CcSEcCtD
Mesalazine—Oedema peripheral—Doxorubicin—muscle cancer	0.000135	0.000787	CcSEcCtD
Mesalazine—Dysgeusia—Methotrexate—muscle cancer	0.000135	0.000786	CcSEcCtD
Mesalazine—Asthenia—Etoposide—muscle cancer	0.000135	0.000785	CcSEcCtD
Mesalazine—Connective tissue disorder—Doxorubicin—muscle cancer	0.000135	0.000785	CcSEcCtD
Mesalazine—Urethral disorder—Doxorubicin—muscle cancer	0.000135	0.000783	CcSEcCtD
Mesalazine—Back pain—Methotrexate—muscle cancer	0.000134	0.000777	CcSEcCtD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000133	0.00128	CbGpPWpGaD
Mesalazine—Pruritus—Etoposide—muscle cancer	0.000133	0.000774	CcSEcCtD
Mesalazine—IKBKB—Apoptosis Modulation and Signaling—TP53—muscle cancer	0.000133	0.00127	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000132	0.00127	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KIDINS220—muscle cancer	0.000132	0.00127	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—FOXO4—muscle cancer	0.000131	0.00126	CbGpPWpGaD
Mesalazine—Vision blurred—Methotrexate—muscle cancer	0.00013	0.000757	CcSEcCtD
Mesalazine—Erythema multiforme—Doxorubicin—muscle cancer	0.00013	0.000755	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—KIT—muscle cancer	0.000129	0.00124	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.000129	0.00124	CbGpPWpGaD
Mesalazine—Diarrhoea—Etoposide—muscle cancer	0.000129	0.000749	CcSEcCtD
Mesalazine—Eye disorder—Doxorubicin—muscle cancer	0.000128	0.000746	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—muscle cancer	0.000128	0.000745	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—muscle cancer	0.000128	0.000745	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—muscle cancer	0.000128	0.000742	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—muscle cancer	0.000127	0.000741	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—FOXO4—muscle cancer	0.000126	0.00121	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—MDM2—muscle cancer	0.000126	0.0012	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—ENO2—muscle cancer	0.000125	0.0012	CbGpPWpGaD
Mesalazine—Angiopathy—Doxorubicin—muscle cancer	0.000125	0.000725	CcSEcCtD
Mesalazine—Malaise—Methotrexate—muscle cancer	0.000125	0.000724	CcSEcCtD
Mesalazine—Dizziness—Etoposide—muscle cancer	0.000124	0.000724	CcSEcCtD
Mesalazine—Immune system disorder—Doxorubicin—muscle cancer	0.000124	0.000721	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—muscle cancer	0.000124	0.000721	CcSEcCtD
Mesalazine—Mediastinal disorder—Doxorubicin—muscle cancer	0.000124	0.00072	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—muscle cancer	0.000124	0.000719	CcSEcCtD
Mesalazine—Chills—Doxorubicin—muscle cancer	0.000123	0.000717	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—muscle cancer	0.000121	0.000706	CcSEcCtD
Mesalazine—Cough—Methotrexate—muscle cancer	0.00012	0.000701	CcSEcCtD
Mesalazine—Mental disorder—Doxorubicin—muscle cancer	0.00012	0.0007	CcSEcCtD
Mesalazine—Vomiting—Etoposide—muscle cancer	0.00012	0.000696	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—muscle cancer	0.00012	0.000695	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—FOXO4—muscle cancer	0.000119	0.00114	CbGpPWpGaD
Mesalazine—Rash—Etoposide—muscle cancer	0.000119	0.00069	CcSEcCtD
Mesalazine—Dermatitis—Etoposide—muscle cancer	0.000119	0.000689	CcSEcCtD
Mesalazine—Headache—Etoposide—muscle cancer	0.000118	0.000685	CcSEcCtD
Mesalazine—Flatulence—Doxorubicin—muscle cancer	0.000118	0.000685	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—muscle cancer	0.000118	0.000684	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—muscle cancer	0.000118	0.000684	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—muscle cancer	0.000118	0.000684	CcSEcCtD
Mesalazine—IKBKB—Signaling by NGF—KIT—muscle cancer	0.000117	0.00113	CbGpPWpGaD
Mesalazine—Tension—Doxorubicin—muscle cancer	0.000117	0.000682	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—muscle cancer	0.000117	0.000681	CcSEcCtD
Mesalazine—PPARG—Developmental Biology—FOXO1—muscle cancer	0.000117	0.00112	CbGpPWpGaD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000117	0.000679	CcSEcCtD
Mesalazine—Discomfort—Methotrexate—muscle cancer	0.000116	0.000675	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—muscle cancer	0.000116	0.000675	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—muscle cancer	0.000116	0.000673	CcSEcCtD
Mesalazine—Muscle spasms—Doxorubicin—muscle cancer	0.000115	0.000669	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—FOXO4—muscle cancer	0.000114	0.0011	CbGpPWpGaD
Mesalazine—Confusional state—Methotrexate—muscle cancer	0.000114	0.000661	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—muscle cancer	0.000113	0.000655	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—muscle cancer	0.000113	0.000655	CcSEcCtD
Mesalazine—CHUK—Immune System—CD34—muscle cancer	0.000112	0.00108	CbGpPWpGaD
Mesalazine—Infection—Methotrexate—muscle cancer	0.000112	0.000651	CcSEcCtD
Mesalazine—Nausea—Etoposide—muscle cancer	0.000112	0.00065	CcSEcCtD
Mesalazine—Ill-defined disorder—Doxorubicin—muscle cancer	0.000111	0.000645	CcSEcCtD
Mesalazine—Nervous system disorder—Methotrexate—muscle cancer	0.000111	0.000643	CcSEcCtD
Mesalazine—Anaemia—Doxorubicin—muscle cancer	0.00011	0.000643	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—muscle cancer	0.00011	0.000642	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—muscle cancer	0.000109	0.000637	CcSEcCtD
Mesalazine—Hyperhidrosis—Methotrexate—muscle cancer	0.000109	0.000634	CcSEcCtD
Mesalazine—PPARG—Gene Expression—MED12—muscle cancer	0.000109	0.00104	CbGpPWpGaD
Mesalazine—Malaise—Doxorubicin—muscle cancer	0.000108	0.000627	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—muscle cancer	0.000107	0.000625	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—muscle cancer	0.000107	0.000625	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—muscle cancer	0.000107	0.000624	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—muscle cancer	0.000107	0.000622	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000107	0.00102	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000106	0.00101	CbGpPWpGaD
Mesalazine—Palpitations—Doxorubicin—muscle cancer	0.000106	0.000614	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—muscle cancer	0.000105	0.000612	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—muscle cancer	0.000105	0.000611	CcSEcCtD
Mesalazine—PTGS1—Metabolism—FH—muscle cancer	0.000105	0.00101	CbGpPWpGaD
Mesalazine—Cough—Doxorubicin—muscle cancer	0.000104	0.000607	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—muscle cancer	0.000103	0.0006	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000103	0.000597	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—muscle cancer	0.000102	0.000593	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—MDM2—muscle cancer	0.000102	0.000977	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD34—muscle cancer	0.000102	0.000977	CbGpPWpGaD
Mesalazine—Myalgia—Doxorubicin—muscle cancer	0.000102	0.000592	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—muscle cancer	0.000102	0.000592	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—muscle cancer	0.000102	0.000592	CcSEcCtD
Mesalazine—Anxiety—Doxorubicin—muscle cancer	0.000101	0.00059	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—muscle cancer	0.000101	0.000588	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000101	0.000588	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—muscle cancer	0.000101	0.000585	CcSEcCtD
Mesalazine—Dyspnoea—Methotrexate—muscle cancer	0.0001	0.000584	CcSEcCtD
Mesalazine—Somnolence—Methotrexate—muscle cancer	0.0001	0.000583	CcSEcCtD
Mesalazine—Dry mouth—Doxorubicin—muscle cancer	9.95e-05	0.000579	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—muscle cancer	9.92e-05	0.000577	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—muscle cancer	9.84e-05	0.000572	CcSEcCtD
Mesalazine—Decreased appetite—Methotrexate—muscle cancer	9.8e-05	0.00057	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—muscle cancer	9.76e-05	0.000567	CcSEcCtD
Mesalazine—Anaphylactic shock—Doxorubicin—muscle cancer	9.76e-05	0.000567	CcSEcCtD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	9.75e-05	0.000935	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—TP53—muscle cancer	9.75e-05	0.000935	CbGpPWpGaD
Mesalazine—Gastrointestinal disorder—Methotrexate—muscle cancer	9.73e-05	0.000566	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—muscle cancer	9.71e-05	0.000565	CcSEcCtD
Mesalazine—Infection—Doxorubicin—muscle cancer	9.69e-05	0.000564	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—FOXO1—muscle cancer	9.69e-05	0.000929	CbGpPWpGaD
Mesalazine—Pain—Methotrexate—muscle cancer	9.64e-05	0.00056	CcSEcCtD
Mesalazine—Shock—Doxorubicin—muscle cancer	9.6e-05	0.000558	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—muscle cancer	9.57e-05	0.000557	CcSEcCtD
Mesalazine—Thrombocytopenia—Doxorubicin—muscle cancer	9.55e-05	0.000556	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—muscle cancer	9.52e-05	0.000554	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—muscle cancer	9.48e-05	0.000551	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—muscle cancer	9.43e-05	0.000549	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—FOXO1—muscle cancer	9.3e-05	0.000892	CbGpPWpGaD
Mesalazine—Anorexia—Doxorubicin—muscle cancer	9.3e-05	0.000541	CcSEcCtD
Mesalazine—Feeling abnormal—Methotrexate—muscle cancer	9.29e-05	0.00054	CcSEcCtD
Mesalazine—IKBKB—Signaling by NGF—MDM2—muscle cancer	9.24e-05	0.000886	CbGpPWpGaD
Mesalazine—Gastrointestinal pain—Methotrexate—muscle cancer	9.21e-05	0.000536	CcSEcCtD
Mesalazine—Hypotension—Doxorubicin—muscle cancer	9.12e-05	0.00053	CcSEcCtD
Mesalazine—Urticaria—Methotrexate—muscle cancer	8.95e-05	0.000521	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—muscle cancer	8.91e-05	0.000518	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—muscle cancer	8.91e-05	0.000518	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	8.89e-05	0.000517	CcSEcCtD
Mesalazine—Insomnia—Doxorubicin—muscle cancer	8.82e-05	0.000513	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—FOXO1—muscle cancer	8.78e-05	0.000842	CbGpPWpGaD
Mesalazine—Paraesthesia—Doxorubicin—muscle cancer	8.76e-05	0.00051	CcSEcCtD
Mesalazine—Dyspnoea—Doxorubicin—muscle cancer	8.7e-05	0.000506	CcSEcCtD
Mesalazine—Somnolence—Doxorubicin—muscle cancer	8.67e-05	0.000504	CcSEcCtD
Mesalazine—CHUK—Disease—ENO2—muscle cancer	8.65e-05	0.00083	CbGpPWpGaD
Mesalazine—Dyspepsia—Doxorubicin—muscle cancer	8.59e-05	0.0005	CcSEcCtD
Mesalazine—Decreased appetite—Doxorubicin—muscle cancer	8.48e-05	0.000493	CcSEcCtD
Mesalazine—PPARG—Metabolism—MED12—muscle cancer	8.47e-05	0.000812	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—FOXO1—muscle cancer	8.43e-05	0.000809	CbGpPWpGaD
Mesalazine—Gastrointestinal disorder—Doxorubicin—muscle cancer	8.42e-05	0.00049	CcSEcCtD
Mesalazine—Fatigue—Doxorubicin—muscle cancer	8.41e-05	0.000489	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—muscle cancer	8.34e-05	0.000485	CcSEcCtD
Mesalazine—Pain—Doxorubicin—muscle cancer	8.34e-05	0.000485	CcSEcCtD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	8.34e-05	0.0008	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—FH—muscle cancer	8.33e-05	0.000799	CbGpPWpGaD
Mesalazine—Hypersensitivity—Methotrexate—muscle cancer	8.3e-05	0.000483	CcSEcCtD
Mesalazine—PPARG—Circadian rythm related genes—TP53—muscle cancer	8.26e-05	0.000792	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—TP53—muscle cancer	8.12e-05	0.000778	CbGpPWpGaD
Mesalazine—Asthenia—Methotrexate—muscle cancer	8.08e-05	0.00047	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	8.08e-05	0.000774	CbGpPWpGaD
Mesalazine—Feeling abnormal—Doxorubicin—muscle cancer	8.04e-05	0.000468	CcSEcCtD
Mesalazine—Gastrointestinal pain—Doxorubicin—muscle cancer	7.98e-05	0.000464	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—muscle cancer	7.97e-05	0.000464	CcSEcCtD
Mesalazine—CHUK—Disease—HMGA1—muscle cancer	7.86e-05	0.000754	CbGpPWpGaD
Mesalazine—Urticaria—Doxorubicin—muscle cancer	7.75e-05	0.000451	CcSEcCtD
Mesalazine—PPARG—Metabolism—ENO2—muscle cancer	7.72e-05	0.00074	CbGpPWpGaD
Mesalazine—Abdominal pain—Doxorubicin—muscle cancer	7.71e-05	0.000449	CcSEcCtD
Mesalazine—Body temperature increased—Doxorubicin—muscle cancer	7.71e-05	0.000449	CcSEcCtD
Mesalazine—Diarrhoea—Methotrexate—muscle cancer	7.71e-05	0.000448	CcSEcCtD
Mesalazine—CHUK—Immune System—FOXO4—muscle cancer	7.64e-05	0.000732	CbGpPWpGaD
Mesalazine—Dizziness—Methotrexate—muscle cancer	7.45e-05	0.000433	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—KIT—muscle cancer	7.38e-05	0.000708	CbGpPWpGaD
Mesalazine—Hypersensitivity—Doxorubicin—muscle cancer	7.19e-05	0.000418	CcSEcCtD
Mesalazine—Vomiting—Methotrexate—muscle cancer	7.16e-05	0.000417	CcSEcCtD
Mesalazine—Rash—Methotrexate—muscle cancer	7.1e-05	0.000413	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—muscle cancer	7.1e-05	0.000413	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—KIT—muscle cancer	7.09e-05	0.00068	CbGpPWpGaD
Mesalazine—Headache—Methotrexate—muscle cancer	7.06e-05	0.000411	CcSEcCtD
Mesalazine—CHUK—Disease—FOXO4—muscle cancer	7.05e-05	0.000676	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TP53—muscle cancer	7.03e-05	0.000674	CbGpPWpGaD
Mesalazine—Asthenia—Doxorubicin—muscle cancer	7e-05	0.000407	CcSEcCtD
Mesalazine—IKBKB—Immune System—FOXO4—muscle cancer	6.93e-05	0.000664	CbGpPWpGaD
Mesalazine—Pruritus—Doxorubicin—muscle cancer	6.9e-05	0.000401	CcSEcCtD
Mesalazine—Nausea—Methotrexate—muscle cancer	6.69e-05	0.000389	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—KIT—muscle cancer	6.69e-05	0.000642	CbGpPWpGaD
Mesalazine—Diarrhoea—Doxorubicin—muscle cancer	6.68e-05	0.000388	CcSEcCtD
Mesalazine—Dizziness—Doxorubicin—muscle cancer	6.45e-05	0.000375	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—KIT—muscle cancer	6.43e-05	0.000616	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	6.33e-05	0.000607	CbGpPWpGaD
Mesalazine—Vomiting—Doxorubicin—muscle cancer	6.2e-05	0.000361	CcSEcCtD
Mesalazine—Rash—Doxorubicin—muscle cancer	6.15e-05	0.000358	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—muscle cancer	6.15e-05	0.000357	CcSEcCtD
Mesalazine—Headache—Doxorubicin—muscle cancer	6.11e-05	0.000356	CcSEcCtD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.04e-05	0.000579	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—MED12—muscle cancer	5.93e-05	0.000569	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MDM2—muscle cancer	5.81e-05	0.000557	CbGpPWpGaD
Mesalazine—Nausea—Doxorubicin—muscle cancer	5.8e-05	0.000337	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—PTCH1—muscle cancer	5.74e-05	0.000551	CbGpPWpGaD
Mesalazine—CHUK—Immune System—FOXO1—muscle cancer	5.64e-05	0.000541	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—MDM2—muscle cancer	5.58e-05	0.000535	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ENO2—muscle cancer	5.41e-05	0.000518	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—VEGFA—muscle cancer	5.32e-05	0.00051	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MDM2—muscle cancer	5.27e-05	0.000505	CbGpPWpGaD
Mesalazine—CHUK—Disease—FOXO1—muscle cancer	5.21e-05	0.000499	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTCH1—muscle cancer	5.21e-05	0.000499	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ENO2—muscle cancer	5.12e-05	0.000491	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—FOXO1—muscle cancer	5.12e-05	0.000491	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—MDM2—muscle cancer	5.06e-05	0.000485	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FOXO4—muscle cancer	4.94e-05	0.000474	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CNR1—muscle cancer	4.85e-05	0.000465	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	4.78e-05	0.000459	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—MED12—muscle cancer	4.71e-05	0.000451	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HMGA1—muscle cancer	4.66e-05	0.000447	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FOXO4—muscle cancer	4.48e-05	0.000429	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CNR1—muscle cancer	4.4e-05	0.000422	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTGS2—muscle cancer	4.34e-05	0.000416	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KIT—muscle cancer	4.3e-05	0.000412	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ENO2—muscle cancer	4.29e-05	0.000412	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.23e-05	0.000405	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FOXO4—muscle cancer	4.18e-05	0.000401	CbGpPWpGaD
Mesalazine—CHUK—Disease—KIT—muscle cancer	3.97e-05	0.000381	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF2—muscle cancer	3.96e-05	0.00038	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KIT—muscle cancer	3.9e-05	0.000374	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FOXO1—muscle cancer	3.65e-05	0.00035	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF2—muscle cancer	3.59e-05	0.000345	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MDM2—muscle cancer	3.39e-05	0.000325	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FOXO1—muscle cancer	3.31e-05	0.000317	CbGpPWpGaD
Mesalazine—CHUK—Disease—MDM2—muscle cancer	3.13e-05	0.0003	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FOXO1—muscle cancer	3.09e-05	0.000296	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MDM2—muscle cancer	3.07e-05	0.000294	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—muscle cancer	3.01e-05	0.000289	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KIT—muscle cancer	2.78e-05	0.000266	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—muscle cancer	2.69e-05	0.000258	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KIT—muscle cancer	2.52e-05	0.000242	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KIT—muscle cancer	2.35e-05	0.000225	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MDM2—muscle cancer	2.19e-05	0.00021	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MDM2—muscle cancer	1.98e-05	0.00019	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—muscle cancer	1.88e-05	0.000181	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MDM2—muscle cancer	1.85e-05	0.000178	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—muscle cancer	1.66e-05	0.000159	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—muscle cancer	1.51e-05	0.000145	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—muscle cancer	1.26e-05	0.00012	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—muscle cancer	1.14e-05	0.000109	CbGpPWpGaD
